Integral DiagnosticsASX:IDX -0.50%75 Interest Coverage is 1.97 as of Dec. 2025, which is 65% below its 10-year median of 5.70. GuruFocus rates ASX:IDX with a GF Score™ of 75/100 and a GF Value™ of A$2.78 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 95 Medical Diagnostics & Research companies, Integral Diagnostics ranks worse than 83.16% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Integral Diagnostics's
Operating Income
for the
six
months ended in Dec. 2025 was A$33.3 Mil. Integral Diagnostics's Interest Expense for the
six
months ended in Dec. 2025 was A$-16.9 Mil.
Integral Diagnostics's interest coverage for the quarter that ended in Dec. 2025 was 1.97.
The higher the ratio, the stronger the company's financial strength is.
Warning Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Integral Diagnostics Ltd interest coverage is 2.86, which is low.
The historical rank and industry rank for Integral Diagnostics's Interest Coverage or its related term are showing as below:
ASX:IDX'
s Interest Coverage Range Over the Past 10 Years
Min: 2.13 Med: 5.7 Max: 9.73
Current: 2.86
ASX:IDX's Interest Coverage is ranked worse than 83.16% of 95
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.05
vs ASX:IDX: 2.86
Integral Diagnostics (ASX:IDX) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Integral Diagnostics Interest Coverage Related Terms
Integral Diagnostics Interest Coverage Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:IDX vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Integral Diagnostics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's Interest Coverage falls into.
Integral Diagnostics Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ASX:IDX) has a Interest Coverage of 1.97 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Integral Diagnostics and its competitors. This is 65% below median its historical median of 5.70. Over the past decade, Integral Diagnostics' Interest Coverage has ranged from 2.13 to 9.73. According to the industry distribution chart, Integral Diagnostics ranks #79 out of 95 companies in the Medical Diagnostics & Research industry, placing it in the top 83.2%.
Is Integral Diagnostics' Interest Coverage too high?
Integral Diagnostics' current Interest Coverage of 1.97 is 65% below median its 10-year median of 5.70. Over the past 10 years, this metric has ranged from a low of 2.13 to a high of 9.73. The Medical Diagnostics & Research industry median Interest Coverage is 9.05. Integral Diagnostics' value of 1.97 is 78.2% below this industry median. Based on the distribution chart, Integral Diagnostics ranks #79 out of 95 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Integral Diagnostics has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #79 out of 95 companies for Interest Coverage. This places Integral Diagnostics in the lower half of its industry. The industry median Interest Coverage is 9.05. Integral Diagnostics' value of 1.97 is 78.2% below this benchmark. Historically, Integral Diagnostics' own Interest Coverage has ranged from 2.13 to 9.73 over the past decade. While the company's 10-year median is 5.70 vs. the industry median of 9.05, Integral Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.05, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current Interest Coverage of 1.97 is 78.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current Interest Coverage is 1.97, which is 65% below median its own 10-year median of 5.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.78, compared to a current price of A$2.00 — trading 28.1% below its estimated fair value. The current Interest Coverage is 1.97, which is 65% below median its 10-year median of 5.70 and 78.2% below the Medical Diagnostics & Research industry median of 9.05. Integral Diagnostics' overall GF Score™ is 75/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current Interest Coverage is 1.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of A$2.00 is trading 28.1% below its estimated GF Value™ of A$2.78.
GuruFocus considers Integral Diagnostics to be Modestly Undervalued.
Key valuation signals for ASX:IDX:
Interest Coverage: 1.97 (65% below median its 10-year median of 5.70)
GF Value™: A$2.78 vs. price of A$2.00 (28.1% below fair value)
Industry Position: 78.2% below the Medical Diagnostics & Research median (#79 of 95)
No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
75GF Score
Get the complete analysis for ASX:IDX
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDX has been successfully added to your 
